Next Article in Journal
Remdesivir—Bringing Hope for COVID-19 Treatment
Previous Article in Journal
Contribution of Topical Antioxidants to Maintain Healthy Skin—A Review
Open AccessArticle

Melatonin Potentiates the Therapeutic Effects of Metformin in Women with Metabolic Syndrome

1
Department of Pharmacology and Toxicology, College of Pharmacy, Al Farahidi University, Baghdad 10070, Iraq
2
Faculty of Pharmacy, Al-Rafidain University College, Baghdad 10064, Iraq
3
College of Pharmacy, University of Baghdad, Baghdad 10047, Iraq
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2020, 88(2), 28; https://doi.org/10.3390/scipharm88020028
Received: 1 April 2020 / Revised: 14 May 2020 / Accepted: 15 May 2020 / Published: 3 June 2020
Objective: This study evaluated the effect of melatonin on the response of patients suffering from metabolic syndrome (MEBS) treated with metformin. Design: This study used two-armed groups in a double-blind, randomized controlled clinical trial. Materials and Methods: A randomized double-blind placebo-controlled study was carried out on female patients diagnosed as having MEBS, according to the International Diabetes Federation (IDF) diagnosing criteria of MEBS (2005), from the outpatient clinic in Al-Zahraa Teaching Hospital/Kut, Iraq. They were diagnosed utilizing laboratory and clinical investigations, then randomized into two groups. The first group (group A) was treated with metformin (500 mg) twice daily, in addition to a placebo formula once daily at bedtime for three months. The second group (group B) was treated with metformin (500 mg) twice daily after meals, in addition to melatonin (10 mg) once daily at bedtime for three months. Results: The treatment of patients with MEBS using metformin–melatonin showed an improvement in most MEBS components such as fasting serum glucose (FSG), lipid profile, and body mass index (BMI), in addition to a reduction in insulin resistance and hyperinsulinemia. Simultaneously, there were increments in serum uric acid (UA), leptin, prolactin (PRL), and estradiol levels, while serum progesterone level decreased. Furthermore, patients treated with metformin–placebo showed less improvement in the studied parameters compared to that produced due to the inclusion of melatonin in the treatment protocol. Conclusion: Melatonin improves the effect of metformin on several components of MEBS such as FSG, lipid profile, and BMI, in addition to insulin resistance and hyperinsulinemia, compared to metformin alone. View Full-Text
Keywords: melatonin; metformin; metabolic syndrome melatonin; metformin; metabolic syndrome
Show Figures

Figure 1

MDPI and ACS Style

Abood, S.J.; Abdulsahib, W.K.; Hussain, S.A.; Ismail, S.H. Melatonin Potentiates the Therapeutic Effects of Metformin in Women with Metabolic Syndrome. Sci. Pharm. 2020, 88, 28.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop